Form 4: M33 Growth I L.P. Sells Shares in Oncology Institute, Inc. (TOI)

M33 Growth I L.P., a significant shareholder in Oncology Institute, Inc. (TOI), has sold a portion of its holdings, reducing its direct ownership while maintaining indirect ownership through related entities.

Summary

• M33 Growth I L.P. sold 1,796,468 shares of Oncology Institute, Inc. (TOI) common stock on May 20, 2025, at a price of $2.7129 per share.
• Following the transaction, M33 Growth I L.P. directly owns 14,624,233 shares.
• Additionally, 203,532 shares were sold, with TOI M, LLC holding 1,349,048 shares indirectly.
• M33 Growth I GP LLC, as the general partner of M33 Growth I L.P., may be deemed to beneficially own the shares held by M33 Growth I L.P.
• However, M33 Growth I GP LLC disclaims beneficial ownership except to the extent of its pecuniary interest.
• The reporting entities include M33 Growth I L.P., M33 Growth I GP LLC, and TOI M, LLC, all located at the same address in Boston, MA.
• Gabriel Ling, Managing Member of M33 Growth I GP LLC and TOI M, LLC, signed the Form 4 on behalf of the reporting entities.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the sale of shares by a major shareholder, which could indicate a lack of confidence or a portfolio rebalancing strategy. However, the continued significant holding suggests ongoing interest.

Negatives

• M33 Growth I L.P., a significant shareholder, has reduced its direct stake in Oncology Institute, Inc., which could be perceived negatively by the market.

Risks

• Continued selling pressure from major shareholders like M33 Growth I L.P. could negatively impact TOI's stock price.
• The market may interpret the sale as a lack of confidence in the future prospects of Oncology Institute, Inc.

Industry Context

Sales by major shareholders are common, but the market reaction depends on the size of the sale, the shareholder's reputation, and the company's overall performance and outlook. It is important to monitor if other major shareholders follow suit.

Comparison to Industry Standards

• Comparing this transaction to similar sales by major shareholders in comparable healthcare companies would provide context.
• For example, if a major shareholder in a company like Oak Street Health (OSH) or Agilon Health (AGL) reduced their stake, the market reaction and subsequent stock performance could be analyzed for similarities.
• Benchmarking the size of the sale relative to the total outstanding shares against industry averages for secondary offerings or block trades would also be informative.

Stakeholder Impact

• Shareholders may react negatively to the sale, potentially leading to a decrease in stock price.
• Employees may experience uncertainty if the sale is perceived as a lack of confidence in the company's future.
• The impact on customers, suppliers, and creditors is likely to be minimal unless the sale signals a larger strategic shift.

Key Dates

Keywords

Oncology Institute, TOI, M33 Growth I L.P., Share Sale, Beneficial Ownership, Form 4, M33 Growth I GP LLC, TOI M, LLC